哈喽，大家好，今天小墨这篇评论，主要来分析SKG与倍轻松的赛道之争，拆解差距拉大的核心逻辑。 2025年12月底，健康智能硬件赛道迎来两极分化的关键节点。SKG母公司未来穿戴正式向港交所递交IPO招股书，向资本市场发起新一轮冲击。 几乎在同一时间，其最大竞争对手倍轻松，因涉嫌信息披露违规，公司及实际控制人马学军被证监会立案调查。曾经势均力敌的两大深圳品牌，如今一个 奔赴新征程，一个深陷泥潭，差距已然拉开。 这对同城对手的较量，贯穿智能按摩仪行业的崛起全程。产品重叠、门店相邻、代言人对标，连上市计划都紧紧跟随，最终却因战略选择不同，走出了两 条截然不同的道路。 上市竞速 命运走向分岔 命运的天平却偏向了先上市的倍轻松。未来穿戴因时机不佳，历经两轮问询仍未叩开A股大门，2023年7月无奈撤回申请。之后公司尝试冲击北交所，新 三板挂牌、签署辅导协议均无疾而终，直到2025年8月转向港股。 倍轻松上市后拿到融资，却走上了激进扩张的道路。公司在机场、高铁站大规模开设线下体验店，重仓直营渠道，恰逢行业天花板显现，经营效率持续下 滑。2025年底信披违规被立案前，马学军已减持套现6400万元，引发市场诸多争议。 战略分野 ...

Core Viewpoint - The article discusses the rise and challenges of SKG, a brand known for its massage devices, highlighting its marketing strategies, financial struggles, and the implications of its upcoming IPO [4][20][38]. Group 1: Marketing Strategies - SKG has effectively utilized celebrity endorsements, including high-profile figures like Mei Musk and Wang Yibo, to enhance brand visibility and appeal to younger consumers [4][8][17]. - The brand transitioned from a small appliance manufacturer to a leader in the smart wearable device sector, achieving a 21.5% market share in China by 2024 [4][5]. - SKG's marketing approach includes leveraging social media and popular entertainment platforms to create a lifestyle image around its products, moving away from traditional low-cost competition [9][16]. Group 2: Financial Performance - Despite strong sales growth initially, SKG's revenue growth has stagnated, with a mere 0.2% increase in smart wearable device revenue in recent quarters [20][21]. - The company's total revenue for the first three quarters of 2025 reached 878.19 million RMB, reflecting a 16.22% year-on-year growth, but the growth rate is slowing [20][21]. - SKG's financial practices have raised concerns, particularly regarding high dividend payouts that have significantly reduced available profits, leading to questions about the company's financial health [31][33]. Group 3: Industry Challenges - The massage device market has seen a decline, with the overall market size dropping from 555 billion RMB in 2021 to 452 billion RMB in 2023, indicating a compound annual growth rate of -9.76% [24]. - SKG faces intense competition from both established brands and low-cost alternatives, which has pressured its pricing and market position [38][40]. - The brand's reliance on marketing over product innovation has created vulnerabilities, as consumer demand may not sustain without continuous product development [20][22]. Group 4: IPO and Future Prospects - SKG is making its third attempt to go public, this time targeting the Hong Kong market, which may offer a more favorable environment for consumer brands compared to A-share markets [20][35]. - Concerns about the company's financial practices, including aggressive dividend distributions and insufficient R&D investment, could impact investor confidence and IPO valuation [31][34][37]. - The upcoming IPO is seen as a critical juncture for SKG, with potential implications for its operational sustainability and market strategy moving forward [35][37].

Core Viewpoint - Future Health, the parent company of the SKG massage device brand, has submitted an application for a mainboard listing on the Hong Kong Stock Exchange after a tumultuous IPO journey in China [1][15]. Financial Performance - Future Health reported total revenues of 9.05 billion yuan, 10.46 billion yuan, and 10.45 billion yuan for the years 2022, 2023, and 2024 respectively, with adjusted net profits of 1.37 billion yuan, 1.23 billion yuan, and 1.26 billion yuan, maintaining a gross margin around 50% [1][15]. - For the first three quarters of 2025, the company achieved approximately 8.78 billion yuan in total revenue, a year-on-year increase of 16.2%, and an adjusted net profit of about 1.18 billion yuan, a significant increase of 58.8% compared to the same period in 2024 [2][16]. Product Performance - The sales of the core product, the SKG neck massage device, have stagnated, with sales volume fluctuating and showing a slight increase of 3.2% in the first three quarters of 2025, but revenue from this product category decreased by 1.8% [3][20]. - Other products, such as the eye and waist massage devices, have not developed as expected, with sales declining by 16.8% and 0.8% respectively in the first nine months of 2025 [5][20]. Marketing and R&D - Future Health has heavily invested in marketing, with sales and marketing expenses rising from 1.64 billion yuan in 2022 to 1.98 billion yuan in 2025, while R&D expenses have decreased, leading to a lower R&D expense ratio from 9.1% to 6.6% [7][22]. - The company has relied on celebrity endorsements for marketing, with significant spending on endorsements, which accounted for about 10% of sales and marketing expenses in 2021-2022 [6][21]. Customer Concentration and Financial Health - Future Health's revenue is highly concentrated, with the top five customers contributing over 40% of total revenue, which poses risks to the company's financial stability [11][24]. - The company has been generous with cash dividends, distributing a total of 5.94 billion yuan from 2020 to 2023, while also increasing its bank borrowings by 176.8% to 1.80 billion yuan as of September 30, 2025, raising concerns about its financial management [12][28].

Core Viewpoint - Future Health, the parent company of SKG, has officially terminated its IPO plans on the Beijing Stock Exchange due to strategic development needs, following a series of unsuccessful attempts to go public [2][5][6]. Group 1: Company Overview - Future Health, established in 2007, focuses on smart wearable health products, with its main brand SKG specializing in products like neck and eye massagers, muscle guns, and health watches [3]. - As of September 2023, over 80% of Future Health's revenue comes from wearable health products, with neck and waist massagers being the most significant product lines [3]. Group 2: Financial Performance - Future Health reported revenues of 1.048 billion CNY in the latest period, a slight increase of 0.2% from the previous year, with a net profit of approximately 135.46 million CNY, reflecting a 7% increase [4]. - The company has seen fluctuating revenues over the years, with reported revenues of 10.54 billion CNY in 2021, 9.04 billion CNY in 2022, and around 10.48 billion CNY in 2024 [3]. Group 3: IPO Journey - Future Health's IPO journey has been tumultuous, having previously attempted to list on the ChiNext board before shifting focus to the Beijing Stock Exchange [5][7]. - The company faced multiple setbacks, including two suspensions of its IPO review due to outdated financial documents and a withdrawal of its application after significant scrutiny from regulators regarding its dividend policies and executive compensation [6]. Group 4: Strategic Focus and Marketing - In recent years, Future Health has prioritized international expansion, with SKG accelerating its overseas efforts and signing a strategic investment agreement with Morgan Stanley [8]. - The company has invested heavily in marketing, with sales expenses reaching 118 million CNY in the first half of 2024, accounting for 19.8% of its revenue, although overseas revenue saw a decline of 14.18% during the same period [13].